Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

Fig. 7

Mode-of-action of EnanDIM® molecules: Differential activation of secondary cells. Variation of sequences and thus secondary conformation have an influence on unspecific DNA-uptake by TLR9-positive cells, differential uptake into the respective (early or late) endosomes resulting in either IRF7 or NF-kappaB activation followed by induction of specific cytokine pattern and surface marker expression resulting in differential activation of (TLR9-negative) cell subpopulations, and specific binding to the TLR9 and thus strength of the response and subsequent thresholds for cell activation (which may differ between cell types)

Back to article page